Abstract:Inflammasome activation plays a central role in the development of drug-induced and obesity-associated liver disease. However, the sources and mechanisms of inflammasome-mediated liver damage remain poorly understood. Our aim was to investigate the effect of NLRP3 inflammasome activation on the liver using novel mouse models. We generated global and myeloid cell-specific conditional mutant Nlrp3 knock-in mice expressing the D301N Nlrp3 mutation (ortholog of D303N in human NLRP3), resulting in a hyperactive NLRP3. To study the presence and significance of NLRP3-initiated pyroptotic cell death, we separated hepatocytes from nonparenchymal cells and developed a novel flow-cytometry-based (fluorescence-activated cell sorting; FACS) strategy to detect and quantify pyroptosis in vivo based on detection of active caspase 1 (Casp1)- and propidium iodide (PI)-positive cells. Liver inflammation was quantified histologically by FACS and gene expression analysis. Liver fibrosis was assessed by Sirius Red staining and quantitative polymerase chain reaction for markers of hepatic stellate cell (HSC) activation. NLRP3 activation resulted in shortened survival, poor growth, and severe liver inflammation; characterized by neutrophilic infiltration and HSC activation with collagen deposition in the liver. These changes were partially attenuated by treatment with anakinra, an interleukin-1 receptor antagonist. Notably, hepatocytes from global Nlrp3-mutant mice showed marked hepatocyte pyroptotic cell death, with more than a 5-fold increase in active Casp1/PI double-positive cells. Myeloid cell-restricted mutant NLRP3 activation resulted in a less-severe liver phenotype in the absence of detectable pyroptotic hepatocyte cell death.CONCLUSIONS: Our data demonstrate that global and, to a lesser extent, myeloid-specific NLRP3 inflammasome activation results in severe liver inflammation and fibrosis while identifying hepatocyte pyroptotic cell death as a novel mechanism of NLRP3-mediated liver damage.

NLRP3 Inflammasome Activation Triggers Gasdermin D–independent Inflammation

Activation of GSDME compensates for GSDMD deficiency in a mouse model of NLRP3 inflammasomopathy

Phosphodiesterase 4B is Required for NLRP3 Inflammasome Activation by Positive Feedback with Nrf2 in the Early Phase of LPS- Induced Acute Lung Injury

Gasdermin D is an Executor of Pyroptosis and Required for Interleukin-1Β Secretion

AA467197 Controls the Hyperactivation of the NLRP3 Inflammasome During Infection

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation

Defective Endosome-Tgn Retrograde Transport Promotes NLRP3 Inflammasome Activation

The NLRP3 inflammasome: activation and regulation

A novel Nlrp3 knock-in mouse model with hyperactive inflammasome in development of lethal inflammation

Clostridium perfringens virulence factors are nonredundant activators of the NLRP3 inflammasome

NLRP3 inflammasome activation and cell death

Murine Eosinophils Release IL-1β via a Non-Lytic Mechanism Dependent on Gasdermin D (GSDMD) Expression but Independent of GSDMD Proteolytic Processing

Dntp Catabolism is a Macrophage-Intrinsic Gatekeeper Preventing NLRP3 Inflammasome Hyperactivation

New mitochondrial DNA synthesis enables NLRP3 inflammasome activation

Gasdermin E dictates inflammatory responses by controlling the mode of neutrophil death

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice

Protein kinase D at the Golgi controls NLRP3 inflammasome activation

The NLRP3 inflammasome: molecular activation and regulation to therapeutics